|Articles|May 1, 2002

Pharmaceutical Executive

  • Pharmaceutical Executive-05-01-2002

Pharma Expenditures Keep Rising

The National Institute of Health Care Management made headlines with its report on double-digit increases (17 percent) in retail spending on medicines in 2001. The total reached $155 billion last year, almost double the $80 billion spent in 1997, according to the study, "Another Year of Escalating Costs." PhRMA president Alan Holmer said the increase is a good thing, signifying that more people who need medicines for chronic conditions are being treated and thereby avoiding more expensive medical procedures.

The National Institute of Health Care Management made headlines with its report on double-digit increases (17 percent) in retail spending on medicines in 2001. The total reached $155 billion last year, almost double the $80 billion spent in 1997, according to the study, "Another Year of Escalating Costs." PhRMA president Alan Holmer said the increase is a good thing, signifying that more people who need medicines for chronic conditions are being treated and thereby avoiding more expensive medical procedures.

The report identifies three factors responsible for more spending: an increase in prescribing (39 percent), price hikes (37 percent), and a shift to more expensive drugs (24 percent). The "shift effect" to pricier products was only 24 percent last year, compared with 36 percent from 1999 to 2000, largely because fewer new blockbusters came on the market. Also, the pace of growth may be slowing. Last year's 17 percent increase is less than the 18-19 percent hikes of previous years. But spending could shoot up if the government expands coverage for Medicare beneficiaries .

US. Retail Spending on Perscription Drugs

Even if drug outlays rise more slowly, they still will exceed the growth in spending on physicians and hospitals. Several factors will continue to drive pharmaceutical spend, including expanded use of medicines to treat chronic conditions, increased prescribing by physicians, and heavy marketing of new products.

Articles in this issue

over 24 years ago

Prices, Privacy, Pediatrics

over 24 years ago

Natural Resistance

over 24 years ago

The Truth About E-Health

over 24 years ago

The Shame Game

over 24 years ago

Lloyds Pushes Patent Insurance

over 24 years ago

Enabling Genetic Technologies

over 24 years ago

Products in Trouble

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.